SCHEMBL3752643

SCHEMBL3752643

CC(c1ccccc1)N1C(=O)c2ccccc2C1C(=O)NCc1cccc(F)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 2/20 0.81
P2RX7 Q99572 1/20 0.48
SCN9A Q15858 6/20 0.48
KCNH2 Q12809 4/20 0.48
TDP1 Q9NUW8 1/20 0.46
SCN5A Q14524 3/20 0.46
TSHR P16473 2/20 0.44
MAPT P10636 1/20 0.44
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
NR3C2 P08235 1/20 0.42
MMP1 P03956 1/20 0.42
MMP3 P08254 1/20 0.42
MMP9 P14780 1/20 0.42
PRMT5 O14744 1/20 0.42
WDR77 Q9BQA1 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3755943 0.90 KCNA5 (1.00) KCNA5P2RX7SCN9AKCNH2TDP1
SCHEMBL3750669 0.89 KCNA5 (0.86) KCNA5P2RX7SCN9AKCNH2TDP1
SCHEMBL3754015 0.88 KCNA5 (0.77) KCNA5P2RX7SCN9AKCNH2TDP1
SCHEMBL3750619 0.87 KCNA5 (0.75) KCNA5SCN9AKCNH2TDP1SCN5A
SCHEMBL3744033 0.86 KCNA5 (0.80) KCNA5P2RX7SCN9AKCNH2TDP1
SCHEMBL3749998 0.83 KCNA5 (0.75) KCNA5P2RX7SCN9AKCNH2TDP1
SCHEMBL3745343 0.83 KCNA5 (0.78) KCNA5SCN9AKCNH2TDP1SCN5A
SCHEMBL3745627 0.82 KCNA5 (0.77) KCNA5SCN9AKCNH2TDP1SCN5A
SCHEMBL3749933 0.82 KCNA5 (0.73) KCNA5SCN9AKCNH2TDP1SCN5A
SCHEMBL3750902 0.82 KCNA5 (0.73) KCNA5P2RX7SCN9AKCNH2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US claimed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP claimed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO claimed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US claimed
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias ASTRAZENECA AB (SE) 2010-11-25 US disclosed
EP-2049484-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS AstraZeneca AB (SE) 2009-04-22 EP disclosed
WO-2008008022-A1 ISOINDOLINE DERIVATIVES FOR THE TREATMENT OF ARRHYTHMIAS ASTRAZENECA AB (SE) 2008-01-17 WO disclosed
US-20080015237-A1 NEW COMPOUNDS I/418 ASTRAZENECA AB (SE) 2008-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080015237-A1 NEW COMPOUNDS I/418 KCNH1, KCNH2, KCNH3 KCNA5 69/4885P2RX7 1839/4885SCN9A 119/4885
US-20100298392-A1 Isoindoline Derivatives For The Treatment Of Arrhythmias KCNH1, KCNH2, KCNQ2 KCNA5 72/4885P2RX7 1138/4885SCN9A 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.